Chimeric Therapeutics (ASX:CHM) Price-to-Operating-Cash-Flow : (As of Jun. 02, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Chimeric Therapeutics Price-to-Operating-Cash-Flow?

As of today (2024-06-02), Chimeric Therapeutics's share price is A$0.018. Chimeric Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02. Hence, Chimeric Therapeutics's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for Chimeric Therapeutics's Price-to-Operating-Cash-Flow or its related term are showing as below:

ASX:CHM's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 25.775
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

Chimeric Therapeutics's Cash Flow from Operations per share for the six months ended in Dec. 2023 was A$-0.01. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

Chimeric Therapeutics Price-to-Operating-Cash-Flow Historical Data

The historical data trend for Chimeric Therapeutics's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimeric Therapeutics Price-to-Operating-Cash-Flow Chart

Chimeric Therapeutics Annual Data

Trend

Jun21

Jun22

Jun23

Price-to-Operating-Cash-Flow

Chimeric Therapeutics Semi-Annual Data
	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Price-to-Operating-Cash-Flow	Get a 7-Day Free Trial			-	-	-	-	-

Competitive Comparison of Chimeric Therapeutics's Price-to-Operating-Cash-Flow

For the Biotechnology subindustry, Chimeric Therapeutics's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chimeric Therapeutics's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimeric Therapeutics's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Chimeric Therapeutics's Price-to-Operating-Cash-Flow falls into.

Chimeric Therapeutics Price-to-Operating-Cash-Flow Calculation

Chimeric Therapeutics's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	0.018	/	-0.016
	=

Chimeric Therapeutics's Share Price of today is A$0.018.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Chimeric Therapeutics's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.02.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

Chimeric Therapeutics Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Chimeric Therapeutics's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

Chimeric Therapeutics (ASX:CHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimeric Therapeutics Ltd (ASX:CHM) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

CHMMF:USA

Address

62 Lygon Street, Level 3, Carlton South, Melbourne, VIC, AUS, 3053

Website

https://www.chimerictherapeutics.com

Chimeric Therapeutics Ltd is a biotechnology company engaged in developing a cancer cell therapy drug. Its technology CLTX-CAR T uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. Primary products under development by the company are NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company has one segment being the research, development and commercialization of health technologies.

Chimeric Therapeutics (ASX:CHM) Headlines

No Headlines